Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia

Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia

Aberrant PI3K/AKT signaling is a hallmark of acute B-lymphoblastic leukemia (B‑ALL) resulting in increased tumor cell proliferation and apoptosis deficiency. While previous AKT inhibitors struggled with selectivity, MK‑2206 promises meticulous pan‑AKT targeting with proven anti-tumor activity. We he...

Full description

Bibliographic Details
Main Authors:	Anna Richter, Elisabeth Fischer, Clemens Holz, Julia Schulze, Sandra Lange, Anett Sekora, Gudrun Knuebel, Larissa Henze, Catrin Roolf, Hugo Murua Escobar, Christian Junghanss
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Series:	International Journal of Molecular Sciences
Subjects:	AKT inhibition MK‑2206 acute lymphoblastic leukemia venetoclax apoptosis
Online Access:	https://www.mdpi.com/1422-0067/22/5/2771

Similar Items

Combination of Rapamycin and MK-2206 Induced Cell Death via Autophagy and Necroptosis in MYCN-Amplified Neuroblastoma Cell Lines
by: Yudi Dong, et al.
Published: (2020-02-01)

MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation
by: Jin PP, et al.
Published: (2016-07-01)

Downregulation of ATXN3 Enhances the Sensitivity to AKT Inhibitors (Perifosine or MK-2206), but Decreases the Sensitivity to Chemotherapeutic Drugs (Etoposide or Cisplatin) in Neuroblastoma Cells
by: Baocheng Gong, et al.
Published: (2021-07-01)

The Combination of MK-2206 and WZB117 Exerts a Synergistic Cytotoxic Effect Against Breast Cancer Cells
by: Yu-Liang Li, et al.
Published: (2019-11-01)

Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature
by: Nosha Farhadfar, et al.
Published: (2021-09-01)

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia
by: Elisabetta Zappone, et al.
Published: (2020-10-01)

Genetic Analysis and Targeted Therapy Using Buparlisib and MK2206 in a Patient with Triple Metachronous Cancers of the Kidney, Prostate, and Squamous Cell Carcinoma of the Lung: A Case Report
by: Zhao T, et al.
Published: (2021-04-01)

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
by: Elizabeth K. Lee, et al.
Published: (2020-05-01)

Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?
by: Joel D. Leverson, et al.
Published: (2018-10-01)

Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells
by: Kyung Hwan Kim, et al.
Published: (2020-09-01)

CCNG2 Overexpression Mediated by AKT Inhibits Tumor Cell Proliferation in Human Astrocytoma Cells
by: Danfeng Zhang, et al.
Published: (2018-04-01)

Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
by: Xiang Zhang, et al.
Published: (2021-05-01)

Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions
by: Haneen T. Salah, et al.
Published: (2021-06-01)

Venetoclax: evidence to date and clinical potential
by: Luis Miguel Juárez-Salcedo, et al.
Published: (2019-10-01)

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)
by: T. E. Byalik
Published: (2018-07-01)

Positive Effects of PI3K/Akt Signaling Inhibition on PTEN and P53 in Prevention of Acute Lymphoblastic Leukemia Tumor Cells
by: Elahe Naderali, et al.
Published: (2019-08-01)

On the Stability and Degradation Pathways of Venetoclax under Stress Conditions
by: Nina Žigart, et al.
Published: (2020-07-01)

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
by: Schieber M, et al.
Published: (2019-03-01)

Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells
by: Jing-Quan Wang, et al.
Published: (2020-02-01)

Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience
by: Matteo Piccini, et al.
Published: (2021-04-01)

Supersaturated Lipid-Based Formulations to Enhance the Oral Bioavailability of Venetoclax
by: Niklas J. Koehl, et al.
Published: (2020-06-01)

Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements
by: C. Roolf, et al.
Published: (2018-05-01)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
by: Bachar Samra, et al.
Published: (2020-11-01)

Review of Venetoclax in CLL, AML and Multiple Myeloma
by: Masa Lasica, et al.
Published: (2021-05-01)

CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements
by: Delin Yuan, et al.
Published: (2021-03-01)

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
by: Grabinski Nicole, et al.
Published: (2012-11-01)

Abivertinib synergistically strengthens the anti‐leukemia activity of venetoclax in acute myeloid leukemia in a BTK‐dependent manner
by: Shujuan Huang, et al.
Published: (2020-10-01)

225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models
by: Ravendra Garg, et al.
Published: (2021-02-01)

MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
by: Deepak Kumar Shukla, et al.
Published: (2021-01-01)

B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma
by: Amber Loren O. King, BA, et al.
Published: (2021-02-01)

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
by: Stefanie Jilg, et al.
Published: (2019-04-01)

Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified
by: Kaiqi Liu, et al.
Published: (2021-09-01)

Development of venetoclax for therapy of lymphoid malignancies
by: Zhu H, et al.
Published: (2017-03-01)

Loss of G-Protein Pathway Suppressor 2 Promotes Tumor Growth Through Activation of AKT Signaling
by: Stefanie Chan, et al.
Published: (2021-01-01)

Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer
by: Douglas K. Marks, et al.
Published: (2020-06-01)

Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials
by: Qingfang Li, et al.
Published: (2019-06-01)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
by: Ferrarini, I., et al.
Published: (2022)

BCL-2 Inhibitor Venetoclax Induces Autophagy-Associated Cell Death, Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells
by: Alhoshani A, et al.
Published: (2020-12-01)

SYM 2206 (a potent non-competitive AMPA receptor antagonist) elevates the threshold for maximal electroshock-induced seizures in mice
by: Luszczki Jarogniew J., et al.
Published: (2014-06-01)

In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia
by: Alexia Vereertbrugghen, et al.
Published: (2021-07-01)